Saturday, 27 May 2017

ICON appoints APAC and Japan VPs

03 November 2015 | News | By BioSpectrum Bureau

ICON appoints APAC and Japan heads

ICON has made new appointments for APAC and Japan regions

ICON has made new appointments for APAC and Japan regions

Singapore: ICON, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has appointed Ms Mary Pan as vice president, Asia Pacific and Hiroshi Ichikawa as vice president and general manager of ICON's operations in Japan.

Ms Mary brings to ICON over 15 years of global pharmaceutical and clinical development expertise with a strong track record in Asia. Mary joins ICON from Becton Dickinson, a leading medical technology company, where she was head of strategy and innovation in Asia.

Prior to the appointment, Ms Mary was managing director, Asia-Pacific, for ClinTec International. Hiroshi Ichikawa joins ICON with 30 years of CRO and pharmaceutical industry experience in Japan. Prior to ICON, Ichikawa-san was executive vice president and senior director of the Regulatory Science Department at A2Healthcare Corporation, an ITOCHU company.

Commenting on the appointments, Dr. Nuala Murphy, president, ICON Clinical Research Services, said, "Asia-Pacific continues to be an important region for our clients and we are committed to growing our presence and enhancing our capabilities in the region. I'm delighted to welcome Mary and Ichikawa-san to the leadership team in Asia. Their strong knowledge of the Asian clinical development landscape, coupled with their demonstrated leadership in growing successful operations in Asia, will be invaluable as we look to expand in this important region."

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Will biobanking change healthcare in the world?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls